Jody A. Charnow

2 months ago | renalandurologynews.com | Jody A. Charnow

Active surveillance may be a feasible option for selected patients with 4.1-7.0 cm renal masses, data presented at the European Association of Urology’s 2025 Congress (EAU25) in Madrid, Spain, suggest. Banna Hussain, DO, MPH, of the Vattikuti Urology Institute at Henry Ford Hospital in Detroit, Michigan, and colleagues studied 1134 patients with cT1b renal masses identified using the Michigan Urological Surgery Improvement Collaborative (MUSIC) kidney registry.

2 months ago | renalandurologynews.com | Jody A. Charnow

The incidence of urinary tract infections (UTIs) following radical cystectomy differs by post-operative time point and patient risk factors, investigators reported at the European Association of Urology’s 40th Congress in Madrid, Spain. Maxwell Sandberg, MD, of Atrium Health, Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and colleagues retrospectively studied 386 patients who underwent radical cystectomy for bladder cancer from 2012 to 2024.

2 months ago | renalandurologynews.com | Jody A. Charnow

Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of patients following radical cystectomy without neoadjuvant therapy, investigators reported at the European Association of Urology’s 2025 Congress (EAU25) in Madrid, Spain.

2 months ago | renalandurologynews.com | Jody A. Charnow

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the publication has chronicled a remarkable evolution in the management of genitourinary diseases. Take prostate cancer, for example.

2 months ago | oncologynurseadvisor.com | Jody A. Charnow

Use of rectal spacers during prostate radiotherapy (RT) is associated with a lower prevalence of erectile dysfunction (ED), according to real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California. The finding is from a study that included 247,250 patients with prostate cancer receiving prostate RT (intensity-modulated RT, stereotactic body RT, brachytherapy, or proton therapy) across 3132 US counties from 2015 to 2022.